Figure 5.
Figure 5. Receipt of high-dose glucocorticoids and GVHD is associated with viral epitope recognition at d100. In univariate analysis, presence of GVHD was not associated with VirScan metrics, but high-dose steroids (>1 mg/kg prednisone equivalents per day given within 2 weeks prior to analysis) was associated with lower total and non-CMV epitopes. Due to interaction of steroid dose and presence of GVHD, we present this analysis stratified by prior diagnosis of GVHD. In the non-GVHD group, <0.5 mg/kg, n = 15; 0.5-1 mg/kg, n = 7; >1 mg/kg, n = 1. In the GVHD group, <0.5 mg/kg, n = 3; 0.5-1 mg/kg, n = 3; >1 mg/kg, n = 1. At d365, there were no statistically significant differences between groups.

Receipt of high-dose glucocorticoids and GVHD is associated with viral epitope recognition at d100. In univariate analysis, presence of GVHD was not associated with VirScan metrics, but high-dose steroids (>1 mg/kg prednisone equivalents per day given within 2 weeks prior to analysis) was associated with lower total and non-CMV epitopes. Due to interaction of steroid dose and presence of GVHD, we present this analysis stratified by prior diagnosis of GVHD. In the non-GVHD group, <0.5 mg/kg, n = 15; 0.5-1 mg/kg, n = 7; >1 mg/kg, n = 1. In the GVHD group, <0.5 mg/kg, n = 3; 0.5-1 mg/kg, n = 3; >1 mg/kg, n = 1. At d365, there were no statistically significant differences between groups.

Close Modal

or Create an Account

Close Modal
Close Modal